Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 274

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 274
---
 delivered to APx a notice waiving its entitlement to the payment of its deferred underwriting fee with respect to the Business Combination with the Company, declining to serve in any capacity in connection with the Business Combination with the Company, confirming that it does not have any role with respect to the Business Combination with the Company and disclaiming any responsibility for any portion of this proxy statement/prospectus. On November 11, 2022, Mr. Bransfield was introduced to Mr. Calmet, the Chief Executive Officer of Heritas Argentina, by Mr. Trucco, a director of Bioceres Group PLC, to begin conversations regarding the future of Heritas Argentina as an affiliate of Bioceres, as Mr. Bransfield had successfully executed business combination transactions in the past. Mr. Bransfield served as director and Chief Executive Officer of Union Acquisition Corp, and Union Acquisition Corp. II, leading the companies through successful mergers with Bioceres Crop Solutions (NASDAQ: BIOX) and Procaps Group (NASDAQ: PROC) in March 2019 and September 2021, respectively. Mr. Bransfield previously served on the board of Procaps Group and sat on the audit committee and the mergers and acquisitions committee. Following Lightjump Acquisition Corp’s successful business combination with Moolec Science Ltd. (NASDAQ: MLEC) in December 2022, Mr. Bransfield now serves as a board member on its compensation and audit committees. On November 16, 2022, Messrs. Bransfield and Calmet met through a video call to discuss the possibility of creating a new business, OmnigenicsAI, and discuss the possibility of pursuing a business combination transaction with the objective of obtaining access to capital and pursuing opportunities to further develop the business globally. Capital raising opportunities in the market were discussed in addition to the unique position that OmnigenicsAI would have as a result of its two existing business units, Rewell and Heritas. The strategic vision was to create OmnigenicsAI as a part of a rebranding initiative for Heritas Argentina, separating it into two existing business units, integrating genomics and artificial intelligence, and establishing a new company poised for international growth through business development initiatives and potential mergers and acquisitions. Mr.Bransfield determined that, if he intended to pursue to the proposed transaction, he would purchase a SPAC and act as its sponsor. Mr.Bransfield elected to perform diligence on OmnigenicsAI in advance of such purchase. 123 Between February